The role of the therapeutic promise of targeted angiogenesis inhibitor in management of metastatic colorectal cancer

Cancer Therapy

Volumn 9, Issue , 2013, Pages 55-64

  Abubakr, Yousif ^a   Ahmed, Yasar A A ^b  

^a St Vincent's Medical Center Jacksonville   (United States)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Antiangiogenic; Bevacizumab; Colorectal cancer; Target therapy

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; CYTOTOXIC AGENT; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NINTEDANIB; OXALIPLATIN; PANITUMUMAB; PLACEBO; PLACENTAL GROWTH FACTOR; RAMUCIRUMAB; REGORAFENIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB;

ABDOMINAL PAIN; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FATIGUE; FOOT SKIN REACTION; HAND SKIN REACTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INFECTION; INTESTINE PERFORATION; LUNG CANCER; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEOVASCULARIZATION (PATHOLOGY); NEUTROPENIA; NOSE SEPTUM PERFORATION; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENCE FREE SURVIVAL; SALVAGE THERAPY; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOSIS; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUMOR MICROENVIRONMENT; TUMOR NEOVASCULARIZATION; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

EID: 84885081315     PISSN: 15439135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Allegra C, Tabernero J, Lakomy R, et al. Effects of prior bevacizumab use onoutcomes from the VELOUR study: a phase 3 study of aflibercept and FOLFIRI in patients with metastatic colorectal cancer after failure of an oxaliplatin regimen. J Clin Oncol. 30, 2012 (suppl; abstr 3505).
2. Avastin (bevacizumab) prescribing information. Genentech, Inc. San Francisco, CA. May 2012.
3. Bankhead C. FDA Gives Nod to Aflibercept for Colon Cancer. MedPage Today. August 03, 2012. www.medpagetoday.com/HematologyOncolo gy/ColonCancer/34046. Accessed February 23, 2013.
4. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29-37.
5. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410.
6. Bishop-Bailey D. Tumour vascularisation: a druggable target. Curr Opin Pharmacol. 2009;9:96-101.
7. Chan AT. COX2 expression in adenoma: an imperfect marker for chemoprevention. Gut. 2010;59(5):568-569.
8. Chin KF, Greenman J, Gardiner E, Kumar H, Topping K, Monson J. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer. 2000;83:1425-1431.
9. Cohn AL, Bekaii-Saab T, Bendell JC, et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). 2010 American Society of Clinical Oncology (ASCO) annual meeting. June 4-8, 2010; Chicago, IL. Abstract 3596.
10. Des Guetz G, Uzzan B, Nicolas P, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006;94:1823-1832.
11. Fan F, Schimming A, Jaeger D, et al. Targeting the tumor microenvironment: focus on angiogenesis. J Oncol. 2012; 2012: 281261.
12. Ferrara N, Hillan KJ, Gerber H-P, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400.
13. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69:11-16.
14. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285: 1182-1186.
15. Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev. 2012;38:484-493.
16. Grothey A, Allegra C. Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4(6);301-9.
17. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26:5326-5334.
18. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet. 2013;381(9863):303-12
19. Iwasaki J, Nihira S. Anti-angiogenic therapy against gastrointestinal tract cancers. Jpn J Clin Oncol. 2009;39(9):543-551.
20. Kerbel RS. Tumor angiogenesis. New Engl J Med. 2008;358:2039-2049.
21. Kieran MW, Kalluri R, Cho Y-J. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med. 2012;2(12):a006593.
22. Kwon KA, Kim SH, Oh SY, et al. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer. 2010;10:203-210.
23. Lieu CH, Tran HT, Jiang Z, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting. June 3-7, 2011. Chicago, IL. Abstract 3533.
24. Maccaroni E, Giampieri R, Scartozzi M, et al. Pretreatment levels of serum lactate dehydrogenase (LDH) and clinical outcome in metastatic colorectal cancer patients receiving first-line chemotherapy and bevacizumab. 2012 American Society of Clinical Oncology (ASCO) annual meeting. June 1-4, 2012; Chicago, IL. Abstract 514.
25. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer, version 3.2012. www.nccn.com. Accessed February 23, 2013.
26. Novello S, Ramlau R, Gorbunova VA, et al. Aflibercept in combination with docetaxel for second-line treatment of locally advanced or metastatic nonsmall-cell lung cancer (NSCLC): Final results of a multinational placebo-controlled phase III trial (EFC10261-VITAL). Program and abstracts of the 14th World Conference on Lung Cancer; July 3-7, 2011; Amsterdam, The Netherlands. Abstract O43.06.
27. Regeneron Pharmaceuticals, Inc. Phase 3 trial of aflibercept in metastatic pancreatic cancer discontinued. Press Release. September 11, 2009. Regeneron Pharmaceuticals, Inc. Sanofi and Regeneron announce regulatory and clinical update for Zaltrap (aflibercept). Press Release. April 5, 2012.
28. Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ. Non-steroidal antiinflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011;106:1340-1350.
29. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20:227-230.
30. Scartozzi M, Giampieri R, Maccaroni E, et al. Pretreatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer. 2012;106:799-804.
31. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 2012;320:130-137.
32. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964-3968.
33. Troiani T, Martinelli E, Orditura M, DeVita F, Ciardiello F, Morgillo F. Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. Expert Opin Investig Drugs. 2012;21:949-959.
34. US Food and Drug Administration. FDA approves Zaltrap for metastatic colorectal cancer. www.fda.gov/NewsEvents/Newsroom/Pre ssAnnouncements/ucm314372.htm.Accessed February 23, 2013
35. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499-506.
36. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245-255.